In the spline regression analyses, the risk of CHD decreased progressively with the serum levels of DHEA and DHEAS after adjusting for age, current smoking, current drinking, insurance type, BMI, duration of diabetes, SBP, LDL-C, FBG, HbA1c, and use of GLP-1 receptor agonists or SGLT-2 inhibitors (Figure 4). This evidence concerns the gene GLP1R and coronary artery disorder.